Stifel lowered the firm’s price target on Ultragenyx to $124 from $131 and keeps a Buy rating on the shares. The firm thinks the year-end 2023 rally in biotech, complemented by several M&A headlines during the JPMorgan conference, has “infused some renewed optimism into the space,” but sees that underscoring the significance of each company’s execution and/or the outcome of the clinical catalysts to further build on that momentum. Ultragenyx pre-announced FY23 numbers and the firm has updated its models accordingly, the analyst tells investors. The firm also highlights Ultragenyx as “one of the more busy stocks this year,” with noteworthy readouts across at least two programs – Phase 3 data for DTX-401 and Phase 1/2 data for GTX-102 in Angelman syndrome.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RARE:
- Mereo BioPharma provides update on pipeline progress, corporate developments
- Ultragenyx price target raised to $47 from $43 at Wedbush
- Ultragenyx reports preliminary 2023 revenue $430M-$435M, consensus $435.9M
- Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones
- Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)